LENTIVIRAL VECTORS MARKET ANALYSIS

Market Challenges And Opportunities

Global Lentiviral Vectors Market– Drivers

Increasing licensing agreement by the market key players

Increasing licensing agreement by the market key players is expected to drive the market over the forecast period. For instance, in October 2020, Mustang Bio, Inc., a clinical-stage biopharmaceutical company, and Sirion-Biotech GmbH, a biotechology company, announced a licensing agreement under which Mustang Bio, Inc. has acquired rights to SIRION’s LentiBOOST technology for the development of MB-207, Mustang’s lentiviral gene therapy for the treatment of patients with X-linked severe combined immunodeficiency (“XSCID”), also known as bubble boy disease, who have been previously treated with a hematopoietic stem cell transplantation (“HSCT”) and for whom re-treatment is indicated. LentiBOOST is SIRION’s proprietary non-cytotoxic transduction enhancer for lentiviral vectors

 Increasing collaboration agreement between the market key players

Increasing collaboration agreement between the market key players is expected to drive the market over the forecast period. For instance, in April 2021, Albumedix Ltd., a science-driven company, has announced an extension to its research collaboration with Cobra Biologics, the gene therapy division of Cognate BioServices, a Charles River Laboratories International, Inc. company. The research collaboration focuses on process optimization and stability enhancement in scale-up manufacturing of AAV (adeno-associated virus) and lentiviral vectors through Albumedix' proprietary recombinant human albumin-based product.

Global Lentiviral Vectors Market: Restraints

The possibility of oncogenesis through insertional mutagenesis

The possibility of oncogenesis through insertional mutagenesis is expected to hinder the market growth over the forecast period. So, in-vitro methods such as irradiation and treatment with chemical mutagens of inducing mutation cane be employed. For instance, in March 2021, according to an article published in the Journal of Cancer Molecular targets and Therapeutics, published by the Frontiers, the risk of inserting a gene into a tumor suppressor gene or activating an oncogene is present for the vectors that integrate into the unwanted locations...